IP Library › Granted Patent US 8,802,434
Granted Patent B2
US 8,802,434 · App. 10/581,376 · Granted Aug 12, 2014

Biological cell culture, cell culture media and therapeutic use of biological cells

Inventor: Christopher Martin Bunce (Birmingham, GB)
Assignee: The University of Birmingham
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,802,434
App. No.
10/581,376
Granted
Aug 12, 2014
Kind
B2
Abstract

The protein NM23 is disclosed as an agent for the maintenance of undifferentiated biological cells in culture. The NM23 protein may act as a survival factor for such cultured cells, or to prevent the differentiation and maturation of the cultured cells. The use of NM23 protein is applicable to culture of stem and/or progenitor cells, and particularly to such cells cultured and adapted for therapeutic use. The invention provides methods, media and media supplements for use in the culture of biological cells, and further provides methods of preparing biological cells for therapeutic use, as well as methods of therapy utilising biological cells and medicaments comprising biological cells adapted for therapeutic use.

Claims (15)

1. A method of maintaining stem cells in culture in vitro comprising culturing the stem cells in the presence of NM23 protein, without any cytokines other than cytokines IL-3 and/or SCF, wherein the NM23 acts to inhibit differentiation and maturation of said cultured stem cells.

2. The method of claim 1 , wherein the NM23 protein acts as a survival factor for said cultured stem cells.

3. The method of claim 1 , wherein the cultured stem cells are for therapeutic use.

4. The method of claim 1 , wherein the cultured stem cells are for non-therapeutic use.

5. The method of claim 1 , wherein the cultured stem cells are selected from the group consisting of mesenchymal stem cells, haematopoietic stem cells, stem cells of the central nervous system (CNS) and epidermal stem cells.

6. The method of claim 1 , wherein the stem cells are collected from the blood or bone marrow.

7. A cell culture medium for the promotion of stem cell survival in culture without differentiation, the culture medium comprising:

NM23 protein in an amount sufficient to inhibit differentiation and maturation of the stem cells in the culture; and

an effective amount of cytokine selected from the group consisting of IL-3, SCF, and combinations thereof, and

wherein the medium contains no other cytokines.

8. The cell culture medium according to claim 7 , wherein the stem cell is selected from the group consisting of a mesenchymal stem cell, a haematopoietic stem cell, a stem cell of the central nervous system (CNS), and an epidermal stem cell.

9. The cell culture medium according to claim 7 , wherein the stem cell is collected from blood or bone marrow.

10. The cell culture medium according to claim 7 , wherein the stem cell culture medium comprises RPMI 1640 medium.

11. The cell culture medium according to claim 7 , wherein the stem cell culture medium comprises DMEM medium.

12. A composition comprising the stem cell culture medium according to any of claims 7 - 11 in contact with said stem cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2006
From: BUNCE, CHRISTOPHER MARTIN
To: UNIVERSITY OF BIRMINGHAM, THE
Reel/Frame 018285/0641 →
Priority Claims (1)
GB 0328245.6 · Dec 5, 2003 · national
Continuity (1)
Related Publication 20070243171A1 · Oct 18, 2007